5 reports

OF THESE, ##% OF PATIENTS EXPERIENCE A CHRONIC CONDITION AND ##% OF THESE REQUIRE OPIOIDS FOR PAIN RELIEF.

  • Ovarian Cancer
  • Topical Delivery
  • United States
  • Forecast
  • Nektar Therapeutics

Also additional data showed rapid and sustained pain relief from as early as week ##, which was sustained out to ## years in PsA patients.

  • Biomarker
  • Clinical Trial
  • Ovarian Cancer
  • United States
  • GlobalData's company

Exelixis, Inc. reported interim data on pain relief and related reduction in narcotic analgesic use with cabozantinib in castration-resistant prostate cancer (CRPC) patients with bone metastases.

  • Monoclonal Antibody
  • Ovarian Cancer
  • United States
  • Product Initiative
  • Merck & Co., Inc.

The third patient had stable disease on bone scan. ##-Nov-2011 Exelixis, Inc. reported interim data on pain relief and related reduction in narcotic analgesic use with cabozantinib in castration-resistant prostate cancer (CRPC) patients with bone metastases.

  • Ovarian Cancer
  • United States
  • Company
  • Product Initiative
  • Merck & Co., Inc.

The third patient had stable disease on bone scan. ##-Nov-2011 Exelixis, Inc. reported interim data on pain relief and related reduction in narcotic analgesic use with cabozantinib in castration-resistant prostate cancer (CRPC) patients with bone metastases.

  • Cancer
  • Ovarian Cancer
  • United States
  • Product Initiative
  • Merck & Co., Inc.